Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation
Status:
Unknown status
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
Adjuvant therapy has been proved effective in treating earlier stage or less advanced
non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as
adjuvant therapy in treating stage IIA-IIIA adenocarcinoma patients with EGFR mutation. The
primary endpoint is disease-free survival.